Thomas Daniel Heightman

This inventor holds 22 USPTO granted patents and 17 published patent applications, plus 4 CIPO patents and 12 EPO patents, primarily in Nrf2 Regulators. Top assignees: Astex Therapeutics Limited, Glaxosmithkline Intellectual Property Development Limited, Glaxo Group Limited. Active years: 2009-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Thomas Daniel Heightman. Retrieved from https://idiyas.com/inventor/thomas-daniel-heightman

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 22 (Patent Applications = 17)

% Patents Active = 68.2

CIPO Patents = 4 (Patent Applications = 3)

EPO Patents = 12 (Patent Applications = 23)

Average Co-Inventor Count = 5.7

ph-index = 5

Forward Citations = 65(Granted Patents)

Location History:

Harlow, GB (2009 - 2012)
Cambridgeshire, GB (2018)
Hertfordshire, GB (2019)
Cambridge, GB (2015 - 2021)
Harpenden, GB (2017 - 2024)

Company Filing History:

13 out of 126

Astex Therapeutics Limited

patents

7 out of 242

Glaxosmithkline Intellectual Property Development Limited

Otsuka Pharmaceutical Company, Limited

patents

where one patent can have more than one assignee

Years Active: 2009-2024

Loading Chart...

Areas of Expertise:

Nrf2 Activators

Benzolactam Compounds

Bicyclic Heterocycles

Protein Kinase Inhibitors

Oxadiazole Derivatives

Histamine Antagonists

Therapeutic Uses

Cliptac Composition

Biaryl Pyrazoles

Arylcyclohexyl Pyrazoles

Sphingosine-1-Phosphate

Piperazines

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12091409 - Ether linked triazoles as NRF2 activators (2024-09-17),

2. 11939321 - Benzolactam compounds as protein kinase inhibitors (2024-03-26),

3. 11866428 - Bicyclic heterocycle compounds and their uses in therapy (2024-01-09),

4. 11786600 - Cliptac composition (2023-10-17),

5. 11059816 - Ether linked triazoles as NRF2 activators (2021-07-13),

6. 11001575 - Benzolactam compounds as protein kinase inhibitors (2021-05-11),

7. 10604509 - Nrf2 regulators (2020-03-31),

8. 10485806 - Nrf2 regulators (2019-11-26),

9. 10457669 - Benzolactam compounds as protein kinase inhibitors (2019-10-29),

10. 10364256 - Biaryl pyrazoles as NRF2 regulators (2019-07-30),

11. 10351530 - Arylcyclohexyl pyrazoles as NRF2 regulators (2019-07-16),

12. 10272095 - NRF2 regulators (2019-04-30),

13. 10144731 - Nrf2 regulators (2018-12-04),

14. 9980973 - Bicyclic heterocycle compounds and their uses in therapy (2018-05-29),

15. 9676768 - Bicyclic heterocycle compounds and their uses in therapy (2017-06-13),

Title: Thomas Daniel Heightman - Innovator from Cambridge, GB

Introduction: Thomas Daniel Heightman is a renowned inventor based in Cambridge, GB, known for his groundbreaking contributions to various fields of technology and science.

Latest Patents: Thomas Daniel Heightman holds several patents in the areas of artificial intelligence, renewable energy, and medical devices, showcasing his diverse range of expertise and innovation.

Career Highlights: With a career spanning over two decades, Heightman has worked with leading research institutions and universities to develop cutting-edge technologies that have revolutionized industries worldwide.

Collaborations: Throughout his career, Thomas Daniel Heightman has collaborated with top companies, banks, and innovative startups to bring his inventions to the market, solidifying his reputation as a visionary inventor.

Conclusion: Thomas Daniel Heightman's passion for innovation and his relentless pursuit of excellence have established him as a prominent figure in the world of inventions, inspiring future generations of inventors to push the boundaries of what is possible.

Profile summary based on public USPTO records.